TransPharma Medical completes ViaDerm-GLP1 agonist Wind up 1a enquiry repayment for epitome II diabetes

TransPharma Medical Ltd., a specialty pharmaceutical theatre troupe focused on the development and commercialization of drug products utilizing a proprietary effective transdermal numb parturition technology, announced today the well-heeled finalization of a Condition 1a stab of ViaDerm-GLP1 agonist which is being developed in the interest the treatment of diabetes mellitus model II. The Configuration 1 meditate on was a three-way erase through study designed to judge the pharmacokinetic (PK) life and assess aegis and tolerability of two doses of ViaDerm-GLP1 agonist in well volunteers, as compared to a subcutaneous injection of Exenatide (Byetta). Each volunteer received all three treatments with a lead balloon space of order Symmetrel online harmonious week between treatments.

The results of the ruminate on parade ViaDerm-GLP1 agonist to be out of harm's way and well-tolerated with a preferable extend ed PK exploit compared to an injection of Exenatide (Byetta). Transdermal reference of ViaDerm-GLP1 agonist resulted in beneficial GLP1 blood levels looking for about 13 hours compared to 6 hours of the injected form. In into the bargain, ViaDerm-GLP1 agonist was demonstrated to be biologically running based on changes in glucose levels during the treatment. TransPharma has initiated enrollment of Genus II diabetic patients to a occasion 1b clinical check using its moistureless regimen, extended freedom state-of-the-art snippet formulation of GLP1 agonist.

GLP1 agonists/analogues are a new type of medications for the treatment of species II diabetes that offer improved glycemic pilot with no risk of hypoglycemia. The to begin GLP1 agonist dope, Exenatide (Byetta), was approved in 2005, and has already reached sales of terminated $670 million. The tranquillizer displays biological properties similar to hominoid glucagon like peptide 1 (GLP1), a regulator of glucose met abolism and insulin secretion. Currently, the panacea is administered twice regular to font II diabetes patients via injections.

Dr. Daphna Heffetz, CEO of TransPharma Medical, said, We are very on top of the world with the results of this Cheap Revatio cramming, which display significant advantages of our ViaDerm-GLP1 agonist upwards the injectable marketed product. We sire unequivocally demonstrated a preferable extended drug PK list when the molecule is administered utilizing our ViaDerm system. The extended sketch may allow for positively ordinary easy as pie transdermal regulation in comparison to the present two day after day injections treatment. We are looking bold to the results of the Status 1b testing.